Economic burden of growth hormone deficiency among adults who are at risk for and who have confirmed growth hormone deficiency using US real-world data
Authors:
- Andrew R. HoffmanAHAndrew R. Hoffman
- Subhara RaveendranSRSubhara Raveendran
- Janna ManjelievskaiaJMJanna Manjelievskaia
- Allison S. KomirenkoAKAllison S. Komirenko
- Isabelle WinerIWIsabelle Winer
- Jessamine P. Winer-JonesJWJessamine P. Winer-Jones
- Machaon BonafedeMBMachaon Bonafede
- Alden R. SmithASAlden R. Smith
Open Access
- 23 August 2025
- journal article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 1322-1333
Abstract
BackgroundUnderdiagnosis and the absence of a condition-specific diagnostic code have made the economic burden of adult growth hormone deficiency (AGHD) difficult to capture. This study measured the all-cause and disease-specific healthcare utilization and costs of AGHD among individuals stratified by diagnosis status and receipt of growth hormone (GH) treatment.MethodsAdults meeting ≥1 of the following criteria (1/1/2017-12/31/2021): diagnosis of hypopituitarism or related condition, ≥3 pituitary hormone deficiencies, ≥3 pituitary hormone treatments, or ≥1 GH prescription were identified in the Veradigm Network EHR linked to claims. Individuals were stratified by GH level on or before the earliest qualifying event: confirmed (GH < 3 ng/mL), at-risk (no test result), ruled-out (GH ≥ 3 ng/mL). Confirmed and at-risk individuals were further stratified by GH treatment. An age and gender-matched control cohort without AGHD was identified. Healthcare utilization and costs were measured in the 12 months following the index date. Multivariable modeling compared all-cause and AGHD-related healthcare costs, excluding cost of GH, among diagnosis or treatment status stratified cohorts while adjusting for baseline characteristics.ResultsAmong 54,310 individuals at risk for AGHD and 268 with confirmed AGHD, 3.1% and 9.7% received GH treatment, respectively. Study subjects were, on average, 50 years old and majority female. Adjusted all-cause healthcare costs were higher among at-risk individuals (cost ratio [95% confidence interval]: 2.37 [2.26-2.49]) and among confirmed individuals (2.11 [1.52-3.43]) compared to controls. Adjusted annual AGHD-related costs were lower among confirmed individuals compared to at-risk individuals (0.62 [0.52-0.76]) and among treated individuals compared to untreated individuals (0.55 [0.47-0.64]) for those initiating GH therapy.ConclusionsAll-cause healthcare costs were higher among individuals with confirmed AGHD or at risk for AGHD than among adults without GHD. After excluding the cost of GH therapy, lower adjusted AGHD-related costs were associated with both a confirmed AGHD diagnosis and receipt of GH treatment.Keywords
Funding Information
- Ascendis Pharma
This publication has 22 references indexed in Scilit:
- Prevalence, Treatment Patterns, and Characteristics of US Adults with Confirmed or at Risk for Growth Hormone DeficiencyAdvances in Therapy, 2025
- Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancerNature Reviews Endocrinology, 2022
- Development of a Novel Algorithm to Identify People with High Likelihood of Adult Growth Hormone Deficiency in a US Healthcare Claims DatabaseInternational Journal of Endocrinology, 2022
- The heart in growth hormone (GH) deficiency and the cardiovascular effects of GHAnnales d'Endocrinologie, 2021
- Growth hormone replacement in adults: Real-world data from two large studies in US and EuropeGrowth Hormone & IGF Research, 2020
- Pathogenesis and Diagnosis of Growth Hormone Deficiency in AdultsNew England Journal of Medicine, 2019
- Targeted literature review of the humanistic and economic burden of adult growth hormone deficiencyCurrent Medical Research and Opinion, 2018
- Assessment of quality of life on 4-year growth hormone therapy in Japanese patients with adult growth hormone deficiency: A post-marketing, multicenter, observational studyGrowth Hormone & IGF Research, 2017
- Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort studyThe Lancet Diabetes & Endocrinology, 2015
- Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 CountriesAmerican Journal of Epidemiology, 2011